uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q16.277 | Q16 | What Protein therapies have been approved by the FDA to treat psoriasis? | Cyclosporine is the only Protein therapy approved by the FDA to treat psoriasis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "psoriasis" OR LOWER(mesh_heading) = "psoriasis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100646', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1100773', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1100900', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101027', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101154', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101281', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101408', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101535', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101662', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101789', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1101916', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102043', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102170', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102297', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102424', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102551', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102678', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102805', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1102932', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}, {'UUID': 'DrugTargetsIndication121923_text_1103059', 'drugName': 'Cyclosporine', 'tradeNames_list': "['Capimune', 'Capsorin', 'Cequa', 'Cyclosporine', 'Deximune', 'GengrafIkervis', 'Neoral', 'Optimmune', 'Restasis', 'Restasis multidoseSandimmun', 'Sandimmune', 'Sangcya', 'Vanquoral', 'Verkazia']", 'drugType': 'Protein', 'actionType': 'modulator', 'target': 'ENSG00000196262', 'approvedSymbol': 'PPIA', 'approvedName': 'peptidylprolyl isomerase A', 'yearOfFirstApproval': 1983, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Psoriasis', 'efo_term': 'psoriasis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.821 | Q16 | What Small molecule therapies have been approved by the FDA to treat biliary tract cancer? | There are no drug Small molecule therapies approved to treat biliary tract cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "biliary tract cancer" OR LOWER(mesh_heading) = "biliary tract cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1458 | Q16 | What Small molecule therapies have been approved by the FDA to treat peptic ulcer disease? | There are 2 Small molecule therapy drugs that are approved to treat peptic ulcer disease which are as follows: Celecoxib and Omeprazole. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peptic ulcer disease" OR LOWER(mesh_heading) = "peptic ulcer disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_832949', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833060', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833171', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833282', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833393', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833504', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097970', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098040', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098110', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098180', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098250', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_1098320', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stomach Ulcer', 'efo_term': 'peptic ulcer disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.547 | Q16 | What Small molecule therapies have been approved by the FDA to treat Merkel cell skin cancer? | There are no drug Small molecule therapies approved to treat Merkel cell skin cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "merkel cell skin cancer" OR LOWER(mesh_heading) = "merkel cell skin cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.794 | Q16 | What Small molecule therapies have been approved by the FDA to treat ataxia telangiectasia? | There are no drug Small molecule therapies approved to treat ataxia telangiectasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ataxia telangiectasia" OR LOWER(mesh_heading) = "ataxia telangiectasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.530 | Q16 | What Small molecule therapies have been approved by the FDA to treat Laryngopharyngeal Reflux? | There are no drug Small molecule therapies approved to treat Laryngopharyngeal Reflux. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "laryngopharyngeal reflux" OR LOWER(mesh_heading) = "laryngopharyngeal reflux") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.635 | Q16 | What Small molecule therapies have been approved by the FDA to treat Stevens-Johnson syndrome? | There are 2 Small molecule therapy drugs that are approved to treat Stevens-Johnson syndrome which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stevens-johnson syndrome" OR LOWER(mesh_heading) = "stevens-johnson syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217645', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_217853', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218061', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218269', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218477', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218685', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_218893', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219101', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219309', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219517', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219725', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_219933', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220141', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220349', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220557', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_220765', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_226341', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_226626', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_226911', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_227196', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_227481', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_227766', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228051', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228336', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228621', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_228906', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_229191', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_229476', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_229761', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230046', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230331', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230616', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_230901', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_231186', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_231471', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_231756', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_232041', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}, {'UUID': 'DrugTargetsIndication121923_text_232326', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Stevens-Johnson Syndrome', 'efo_term': 'Stevens-Johnson syndrome'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1112 | Q16 | What Small molecule therapies have been approved by the FDA to treat gliosarcoma? | There are no drug Small molecule therapies approved to treat gliosarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "gliosarcoma" OR LOWER(mesh_heading) = "gliosarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.374 | Q16 | What Small molecule therapies have been approved by the FDA to treat CADASIL? | There are no drug Small molecule therapies approved to treat CADASIL. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cadasil" OR LOWER(mesh_heading) = "cadasil") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1438 | Q16 | What Small molecule therapies have been approved by the FDA to treat pancreatic endocrine carcinoma? | There are no drug Small molecule therapies approved to treat pancreatic endocrine carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pancreatic endocrine carcinoma" OR LOWER(mesh_heading) = "pancreatic endocrine carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1463 | Q16 | What Small molecule therapies have been approved by the FDA to treat peripheral nervous system disease? | There are no drug Small molecule therapies approved to treat peripheral nervous system disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peripheral nervous system disease" OR LOWER(mesh_heading) = "peripheral nervous system disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1002 | Q16 | What Small molecule therapies have been approved by the FDA to treat diverticular disease? | There are no drug Small molecule therapies approved to treat diverticular disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diverticular disease" OR LOWER(mesh_heading) = "diverticular disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.368 | Q16 | What Small molecule therapies have been approved by the FDA to treat Breech presentation? | There are no drug Small molecule therapies approved to treat Breech presentation. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "breech presentation" OR LOWER(mesh_heading) = "breech presentation") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1661 | Q16 | What Small molecule therapies have been approved by the FDA to treat stomatitis? | There are no drug Small molecule therapies approved to treat stomatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stomatitis" OR LOWER(mesh_heading) = "stomatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.565 | Q16 | What Small molecule therapies have been approved by the FDA to treat Neck pain? | There are no drug Small molecule therapies approved to treat Neck pain. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neck pain" OR LOWER(mesh_heading) = "neck pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.385 | Q16 | What Small molecule therapies have been approved by the FDA to treat Chest pain? | Famotidine is the only Small molecule therapy approved by the FDA to treat Chest pain. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chest pain" OR LOWER(mesh_heading) = "chest pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1100334', 'drugName': 'Famotidine', 'tradeNames_list': "['Famotidine', 'Famotidine preservative freeFamotidine preservative free (pharmacy bulk)', 'Fluxid', 'PepcidPepcid ac', 'Pepcid preservative free', 'Pepcid rpd']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000113749', 'approvedSymbol': 'HRH2', 'approvedName': 'histamine receptor H2', 'yearOfFirstApproval': 1986, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Chest Pain', 'efo_term': 'Chest pain'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.24 | Q16 | What Protein therapies have been approved by the FDA to treat Autoimmune Hepatitis? | There are no drug Protein therapies approved to treat Autoimmune Hepatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "autoimmune hepatitis" OR LOWER(mesh_heading) = "autoimmune hepatitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1683 | Q16 | What Small molecule therapies have been approved by the FDA to treat temporomandibular joint disorder? | There are no drug Small molecule therapies approved to treat temporomandibular joint disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "temporomandibular joint disorder" OR LOWER(mesh_heading) = "temporomandibular joint disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.588 | Q16 | What Small molecule therapies have been approved by the FDA to treat Peptic ulcer? | There are 7 Small molecule therapy drugs that are approved to treat Peptic ulcer which are as follows: Dexamethasone, Celecoxib, Omeprazole, Lansoprazole, Dexlansoprazole, Nizatidine, and Famotidine. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "peptic ulcer" OR LOWER(mesh_heading) = "peptic ulcer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_226317', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_226602', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_226887', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_227172', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_227457', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_227742', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_228027', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_228312', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_228597', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_228882', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_229167', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_229452', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_229737', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_230022', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_230307', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_230592', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_230877', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_231162', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_231447', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_231732', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_232017', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_232302', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_832934', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_832949', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833045', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_833060', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833156', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_833171', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833267', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_833282', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833378', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_833393', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_833489', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_833504', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'peptic ulcer disease'}, {'UUID': 'DrugTargetsIndication121923_text_1097964', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098034', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098104', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098174', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098244', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098314', 'drugName': 'Omeprazole', 'tradeNames_list': "['Antra', 'Losec', 'Losec mups', 'Mezzopram', 'Mopral', 'Omeprazole', 'OmeranPrilosec', 'Zanprol']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1989, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098343', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098367', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098391', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098415', 'drugName': 'Lansoprazole', 'tradeNames_list': "['Lansoprazole', 'Opiren', 'Prevacid', 'Prevacid 24 hrPrevacid Delayed Release', 'Prevacid Solutab', 'Prevacid iv', 'Zoton']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000186009', 'approvedSymbol': 'ATP4B', 'approvedName': 'ATPase H+/K+ transporting subunit beta', 'yearOfFirstApproval': 1995, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098421', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098429', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098437', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098445', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098453', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098461', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098469', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098477', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098485', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098493', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098501', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098509', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098517', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098525', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098533', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098541', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098549', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098557', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098565', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098573', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098581', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098589', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098597', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098605', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098613', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098621', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098629', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098637', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098645', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098653', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098661', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098669', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098677', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098685', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098693', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098701', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098709', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098717', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098725', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098733', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098741', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098749', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098757', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098765', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098773', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098781', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098789', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098797', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098805', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098813', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098821', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098829', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098837', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098845', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098853', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}, {'UUID': 'DrugTargetsIndication121923_text_1098861', 'drugName': 'Dexlansoprazole', 'tradeNames_list': "['Dexilant', 'Dexilant solutab', 'Kapidex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105675', 'approvedSymbol': 'ATP4A', 'approvedName': 'ATPase H+/K+ transporting subunit alpha', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Peptic Ulcer', 'efo_term': 'Peptic ulcer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1690 | Q16 | What Small molecule therapies have been approved by the FDA to treat thrombotic disease? | There are 6 Small molecule therapy drugs that are approved to treat thrombotic disease which are as follows: Rivaroxaban, Apixaban, Aspirin, Ticagrelor, Dabigatran Etexilate, and Argatroban. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thrombotic disease" OR LOWER(mesh_heading) = "thrombotic disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_708684', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708719', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708754', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708789', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708824', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708859', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708894', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708929', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708964', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_708999', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709034', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709069', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709104', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709139', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709174', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709209', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709244', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709279', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709314', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709349', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709384', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709419', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709454', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709489', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709524', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709559', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709594', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709629', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709664', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709699', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709734', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709769', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709804', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709839', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709874', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709909', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709944', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_709979', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710014', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710049', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710084', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710119', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710154', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710189', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710224', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710259', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710294', 'drugName': 'Rivaroxaban', 'tradeNames_list': "['Xarelto']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710365', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710394', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710423', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710452', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710481', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710510', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710539', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710568', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710597', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710626', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710655', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710684', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710713', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710742', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_710771', 'drugName': 'Apixaban', 'tradeNames_list': "['Eliquis']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000126218', 'approvedSymbol': 'F10', 'approvedName': 'coagulation factor X', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833656', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833813', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_833970', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_834127', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_834284', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_834441', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_834598', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_834755', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_834912', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_835069', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_835226', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_835383', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_835540', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_835697', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_835854', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_836011', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920340', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920366', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920392', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920418', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920444', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920470', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920496', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920522', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920548', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920574', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920600', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920626', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920652', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920678', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920704', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920730', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920756', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920782', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920808', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920834', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920860', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}, {'UUID': 'DrugTargetsIndication121923_text_920886', 'drugName': 'Ticagrelor', 'tradeNames_list': "['Brilinta', 'Brilique']", 'drugType': 'Small molecule', 'actionType': 'negative allosteric modulator', 'target': 'ENSG00000169313', 'approvedSymbol': 'P2RY12', 'approvedName': 'purinergic receptor P2Y12', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thrombosis', 'efo_term': 'thrombotic disease'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1697 | Q16 | What Small molecule therapies have been approved by the FDA to treat tibia fracture? | There are no drug Small molecule therapies approved to treat tibia fracture. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "tibia fracture" OR LOWER(mesh_heading) = "tibia fracture") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1696 | Q16 | What Small molecule therapies have been approved by the FDA to treat thyroid neoplasm? | Vandetanib is the only Small molecule therapy approved by the FDA to treat thyroid neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thyroid neoplasm" OR LOWER(mesh_heading) = "thyroid neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_209947', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_209995', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210043', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210091', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210139', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210187', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210235', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210283', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210331', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210379', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210427', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210475', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210523', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210571', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210619', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210667', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210715', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210763', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210811', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210859', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210907', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_210955', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211003', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211051', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211099', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211147', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211195', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211243', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211291', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211339', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211387', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211435', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211483', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211531', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211579', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211627', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211675', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211723', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211771', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211819', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211867', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211915', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_211963', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212011', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212059', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212107', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212155', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212203', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212251', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212299', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212347', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212395', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212443', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212491', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212539', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212587', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212635', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212683', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212731', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212779', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212827', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212875', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212923', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_212971', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213019', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213067', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213115', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213163', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213211', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213259', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213307', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213355', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213403', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213451', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213499', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213547', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213595', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213643', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213691', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213739', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213787', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213835', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213883', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213931', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_213979', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214027', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214075', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214123', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214171', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214219', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214267', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214315', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214363', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214411', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214459', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214507', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214555', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214603', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214651', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_214699', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid neoplasm'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1484 | Q16 | What Small molecule therapies have been approved by the FDA to treat plasma cell leukemia? | There are no drug Small molecule therapies approved to treat plasma cell leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "plasma cell leukemia" OR LOWER(mesh_heading) = "plasma cell leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.800 | Q16 | What Small molecule therapies have been approved by the FDA to treat atypical hemolytic-uremic syndrome? | There are no drug Small molecule therapies approved to treat atypical hemolytic-uremic syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "atypical hemolytic-uremic syndrome" OR LOWER(mesh_heading) = "atypical hemolytic-uremic syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.922 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic pancreatitis? | There are no drug Small molecule therapies approved to treat chronic pancreatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic pancreatitis" OR LOWER(mesh_heading) = "chronic pancreatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1214 | Q16 | What Small molecule therapies have been approved by the FDA to treat intracranial hypertension? | There are no drug Small molecule therapies approved to treat intracranial hypertension. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "intracranial hypertension" OR LOWER(mesh_heading) = "intracranial hypertension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1355 | Q16 | What Small molecule therapies have been approved by the FDA to treat myoepithelial tumor? | There are no drug Small molecule therapies approved to treat myoepithelial tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "myoepithelial tumor" OR LOWER(mesh_heading) = "myoepithelial tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1346 | Q16 | What Small molecule therapies have been approved by the FDA to treat musculoskeletal system disease? | There are no drug Small molecule therapies approved to treat musculoskeletal system disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "musculoskeletal system disease" OR LOWER(mesh_heading) = "musculoskeletal system disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.815 | Q16 | What Small molecule therapies have been approved by the FDA to treat berylliosis? | Prednisone is the only Small molecule therapy approved by the FDA to treat berylliosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "berylliosis" OR LOWER(mesh_heading) = "berylliosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217653', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_217861', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_218069', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_218277', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_218485', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_218693', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_218901', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_219109', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_219317', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_219525', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_219733', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_219941', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_220149', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_220357', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_220565', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}, {'UUID': 'DrugTargetsIndication121923_text_220773', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Berylliosis', 'efo_term': 'berylliosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.986 | Q16 | What Small molecule therapies have been approved by the FDA to treat diabetes mellitus? | There are 10 Small molecule therapy drugs that are approved to treat diabetes mellitus which are as follows: Fenofibrate, Linagliptin, Sitagliptin, Amlodipine Benzoate, Telmisartan, Lisinopril, Canagliflozin, Ertugliflozin, Empagliflozin, and Metformin Hydrochloride. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diabetes mellitus" OR LOWER(mesh_heading) = "diabetes mellitus") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_243940', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_243969', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_243998', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244027', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244056', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244085', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244114', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244143', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244172', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244201', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244230', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244259', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244288', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244317', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244346', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244375', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244404', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_244433', 'drugName': 'Fenofibrate', 'tradeNames_list': "['Antara', 'Antara (micronized)', 'Fenofibrate', 'Fenofibrate (micronized)Fenogal', 'Fenoglide', 'Lipantil', 'Lipantil micro 200Lipantil micro 267', 'Lipantil micro 67', 'Lipidil', 'LipofenSupralip 160', 'Tricor', 'Tricor (micronized)', 'Triglide']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000186951', 'approvedSymbol': 'PPARA', 'approvedName': 'peroxisome proliferator activated receptor alpha', 'yearOfFirstApproval': 1993, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932906', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932916', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932926', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932936', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932946', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932956', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932966', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932976', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932986', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_932996', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933006', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933016', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933026', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933036', 'drugName': 'Linagliptin', 'tradeNames_list': "['Tradjenta', 'Trajenta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933327', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933348', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933369', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933390', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933411', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933432', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933453', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933474', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933495', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933516', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933537', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933558', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933579', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933600', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933621', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933642', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933663', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933684', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933705', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933726', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933747', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933768', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933789', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933810', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933831', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933852', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_933873', 'drugName': 'Sitagliptin', 'tradeNames_list': "['Januvia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197635', 'approvedSymbol': 'DPP4', 'approvedName': 'dipeptidyl peptidase 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1043995', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044001', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044007', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044013', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044019', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044025', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044031', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044037', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044043', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044049', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044055', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044061', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044067', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044073', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044079', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044085', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044091', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044097', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044103', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044109', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044115', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044121', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044127', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044133', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044139', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044145', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044151', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044157', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044163', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044169', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044175', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1044181', 'drugName': 'Amlodipine Benzoate', 'tradeNames_list': "['Katerzia']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1072709', 'drugName': 'Telmisartan', 'tradeNames_list': "['Micardis', 'Telmisartan', 'Tolura']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000144891', 'approvedSymbol': 'AGTR1', 'approvedName': 'angiotensin II receptor type 1', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091674', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091681', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091688', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091695', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091702', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091709', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091716', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}, {'UUID': 'DrugTargetsIndication121923_text_1091723', 'drugName': 'Lisinopril', 'tradeNames_list': "['Acemin', 'Carace', 'Lisinopril', 'Lisopress', 'Prinivil', 'Qbrelis', 'Zestril']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000159640', 'approvedSymbol': 'ACE', 'approvedName': 'angiotensin I converting enzyme', 'yearOfFirstApproval': 1987, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Diabetes Mellitus', 'efo_term': 'diabetes mellitus'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.443 | Q16 | What Small molecule therapies have been approved by the FDA to treat Fever? | There are 5 Small molecule therapy drugs that are approved to treat Fever which are as follows: Acetaminophen, Aspirin, Naproxen, Ibuprofen, and Dantrolene Sodium. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "fever" OR LOWER(mesh_heading) = "fever") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828731', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_828836', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_828941', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829046', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829151', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829256', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829361', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829466', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829571', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829676', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829781', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829886', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_829991', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830096', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830201', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830306', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830411', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830516', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830621', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830726', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830831', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_830936', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831041', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831146', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831251', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831356', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831461', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831566', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831671', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831776', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831881', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_831986', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832091', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832196', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832301', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832406', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832511', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832616', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832721', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_832826', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_833639', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_833796', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_833953', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_834110', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_834267', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_834424', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_834581', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_834738', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_834895', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_835052', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_835209', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_835366', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_835523', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_835680', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_835837', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_835994', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838325', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838366', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838407', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838448', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838489', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838530', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838571', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838612', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838653', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838694', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838735', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838776', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838817', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838858', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838899', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838940', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_838981', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839022', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839063', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839104', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839145', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839186', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839227', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839268', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839309', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839350', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839391', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839432', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839473', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839514', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839555', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839596', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839637', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839678', 'drugName': 'Naproxen', 'tradeNames_list': "['Aleve', 'Anaprox', 'Arthrosin 250', 'Arthrosin 250 ec', 'Arthrosin 500Arthrosin 500 ec', 'Condrotec', 'Ec-naprosyn', 'Equiproxen', 'Feminax ultraGrenoxal', 'Kenosyn', 'Laraflex', 'Napratec op', 'Naprosyn', 'Naprosyn 375Naprosyn ec', 'Naproxen', 'Nycopren', 'Pranoxen continus', 'ProsaidRheuflex 250', 'Rheuflex 500', 'Rimoxyn', 'Stirlescent', 'TimpronTimpron 250 ec', 'Timpron 500 ec', 'Valrox', 'Vimovo']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839760', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839839', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839918', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_839997', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_840076', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_840155', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_840234', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_840313', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_840392', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}, {'UUID': 'DrugTargetsIndication121923_text_840471', 'drugName': 'Ibuprofen', 'tradeNames_list': '[\'Aches-n-pain\', \'Advil\', \'Advil liqui-gels\', \'Advil migraine liqui-gelsAnadin joint pain\', \'Anadin liquifast\', \'Anadin period pain reliefAnadin ultra\', \'Apsifen\', \'Apsifen-f\', \'Arthrofen 200\', \'Arthrofen 400Arthrofen 600\', \'Brufen ret\', \'Caldolor\', \'Cap-profen\', "Children\'s advilChildren\'s advil-flavoredChildren\'s elixsureChildren\'s ibuprofenChildren\'s motrinCo-op", \'Codafen continus\', \'Cuprofen for childCuprofen plus\', \'Deep relief\', \'Ebufac\', \'Femafen\', \'Fenbid\', \'Fenbid fteFenpaed\', \'Feverfen\', \'Fleximex\', \'Ibu-slo\', \'Ibu-tab\', \'Ibu-tab 200Ibucalm\', \'Ibuderm\', \'Ibufac\', \'Ibugel\', \'Ibugel fte\', \'Ibular\', \'IbuleveIbumed\', \'Ibumetin\', \'Ibumousse\', \'Ibuprin\', \'Ibuprofen\', \'IbuprohmIbuspray\', \'Ibutime\', \'Inabrin\', "Infant\'s advilInoven", \'IsisfenJunifen\', \'Junior strength advil\', \'Junior strength ibuprofenJunior strength motrin\', \'Lidifen\', \'Lidifen-f\', \'Lobufen\', \'MandafenManorfen\', \'Maxa-gesic\', \'Medipren\', \'Midol\', \'Midol liquid gels\', \'MigrafenMotrin\', \'Motrin ib\', \'Motrin migraine pain\', \'Novaprin\', \'NuprinNurofen 400\', \'Nurofen back pain sr\', \'Nurofen child\', \'Nurofen for childNurofen plus\', \'Nurofen recovery\', \'Nurofen sinus\', \'Nurofen solbOrbifen\', \'Pacifene\', \'Paxofen\', \'Pedea\', \'Pediatric advil\', \'PhensicPhor pain\', \'Phorpain\', \'Phorpain max strgh\', \'Profen\', \'ProflexProflex sr\', \'Relcofen\', \'Rimafen\', \'Rufen\', \'Seclodin\', \'SusprenTab-profen\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1974, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Fever', 'efo_term': 'Fever'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.994 | Q16 | What Small molecule therapies have been approved by the FDA to treat diffuse intrinsic pontine glioma? | There are no drug Small molecule therapies approved to treat diffuse intrinsic pontine glioma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "diffuse intrinsic pontine glioma" OR LOWER(mesh_heading) = "diffuse intrinsic pontine glioma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.522 | Q16 | What Small molecule therapies have been approved by the FDA to treat Kallmann syndrome? | There are no drug Small molecule therapies approved to treat Kallmann syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "kallmann syndrome" OR LOWER(mesh_heading) = "kallmann syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1705 | Q16 | What Small molecule therapies have been approved by the FDA to treat transient ischemic attack? | There are no drug Small molecule therapies approved to treat transient ischemic attack. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "transient ischemic attack" OR LOWER(mesh_heading) = "transient ischemic attack") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.401 | Q16 | What Small molecule therapies have been approved by the FDA to treat Cough? | There are no drug Small molecule therapies approved to treat Cough. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "cough" OR LOWER(mesh_heading) = "cough") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1240 | Q16 | What Small molecule therapies have been approved by the FDA to treat laryngeal neoplasm? | There are no drug Small molecule therapies approved to treat laryngeal neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "laryngeal neoplasm" OR LOWER(mesh_heading) = "laryngeal neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1324 | Q16 | What Small molecule therapies have been approved by the FDA to treat mitochondrial disease? | There are no drug Small molecule therapies approved to treat mitochondrial disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "mitochondrial disease" OR LOWER(mesh_heading) = "mitochondrial disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.299 | Q16 | What Protein therapies have been approved by the FDA to treat stroke? | There are no drug Protein therapies approved to treat stroke. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "stroke" OR LOWER(mesh_heading) = "stroke") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.850 | Q16 | What Small molecule therapies have been approved by the FDA to treat bronchitis? | There are no drug Small molecule therapies approved to treat bronchitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bronchitis" OR LOWER(mesh_heading) = "bronchitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.534 | Q16 | What Small molecule therapies have been approved by the FDA to treat Low back pain? | There are no drug Small molecule therapies approved to treat Low back pain. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "low back pain" OR LOWER(mesh_heading) = "low back pain") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.116 | Q16 | What Protein therapies have been approved by the FDA to treat carcinoid syndrome? | There are no drug Protein therapies approved to treat carcinoid syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "carcinoid syndrome" OR LOWER(mesh_heading) = "carcinoid syndrome") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1638 | Q16 | What Small molecule therapies have been approved by the FDA to treat solitary fibrous tumor? | There are no drug Small molecule therapies approved to treat solitary fibrous tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "solitary fibrous tumor" OR LOWER(mesh_heading) = "solitary fibrous tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1165 | Q16 | What Small molecule therapies have been approved by the FDA to treat hypertrophic cardiomyopathy? | Mavacamten is the only Small molecule therapy approved by the FDA to treat hypertrophic cardiomyopathy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypertrophic cardiomyopathy" OR LOWER(mesh_heading) = "hypertrophic cardiomyopathy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1053243', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053245', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053247', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053249', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053251', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053253', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053255', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053257', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000092054', 'approvedSymbol': 'MYH7', 'approvedName': 'myosin heavy chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053259', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053261', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053263', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053265', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053267', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053269', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053271', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053273', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197616', 'approvedSymbol': 'MYH6', 'approvedName': 'myosin heavy chain 6', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053275', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053277', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053279', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053281', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053283', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053285', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053287', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053289', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000078814', 'approvedSymbol': 'MYH7B', 'approvedName': 'myosin heavy chain 7B', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053291', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053293', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053295', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053297', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053299', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053301', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053303', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053305', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160808', 'approvedSymbol': 'MYL3', 'approvedName': 'myosin light chain 3', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053307', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053309', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053311', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053313', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053315', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053317', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053319', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053321', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111245', 'approvedSymbol': 'MYL2', 'approvedName': 'myosin light chain 2', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053323', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053325', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053327', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053329', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053331', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053333', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053335', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053337', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106631', 'approvedSymbol': 'MYL7', 'approvedName': 'myosin light chain 7', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053339', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053341', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053343', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053345', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053347', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053349', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053351', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}, {'UUID': 'DrugTargetsIndication121923_text_1053353', 'drugName': 'Mavacamten', 'tradeNames_list': "['Camzyos']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198336', 'approvedSymbol': 'MYL4', 'approvedName': 'myosin light chain 4', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Cardiomyopathy, Hypertrophic', 'efo_term': 'hypertrophic cardiomyopathy'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1391 | Q16 | What Small molecule therapies have been approved by the FDA to treat nutritional disorder? | There are no drug Small molecule therapies approved to treat nutritional disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "nutritional disorder" OR LOWER(mesh_heading) = "nutritional disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.510 | Q16 | What Small molecule therapies have been approved by the FDA to treat IgG4-related disease? | There are no drug Small molecule therapies approved to treat IgG4-related disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "igg4-related disease" OR LOWER(mesh_heading) = "igg4-related disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1490 | Q16 | What Small molecule therapies have been approved by the FDA to treat poisoning? | There are no drug Small molecule therapies approved to treat poisoning. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "poisoning" OR LOWER(mesh_heading) = "poisoning") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.408 | Q16 | What Small molecule therapies have been approved by the FDA to treat Desmoid-type fibromatosis? | There are no drug Small molecule therapies approved to treat Desmoid-type fibromatosis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "desmoid-type fibromatosis" OR LOWER(mesh_heading) = "desmoid-type fibromatosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1478 | Q16 | What Small molecule therapies have been approved by the FDA to treat pigmented villonodular synovitis? | There are no drug Small molecule therapies approved to treat pigmented villonodular synovitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pigmented villonodular synovitis" OR LOWER(mesh_heading) = "pigmented villonodular synovitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1482 | Q16 | What Small molecule therapies have been approved by the FDA to treat placenta praevia? | There are no drug Small molecule therapies approved to treat placenta praevia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "placenta praevia" OR LOWER(mesh_heading) = "placenta praevia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1553 | Q16 | What Small molecule therapies have been approved by the FDA to treat pulmonary tuberculosis? | There are 3 Small molecule therapy drugs that are approved to treat pulmonary tuberculosis which are as follows: Prednisone, Triamcinolone Acetonide, and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulmonary tuberculosis" OR LOWER(mesh_heading) = "pulmonary tuberculosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217663', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_217871', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218079', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218287', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218495', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218703', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_218911', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219119', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219327', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219535', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219743', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_219951', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220159', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220367', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220575', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_220783', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_221880', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_221945', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_222010', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_222075', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_222140', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_222205', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_222270', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_222335', 'drugName': 'Triamcinolone Acetonide', 'tradeNames_list': "['Adcortyl', 'Adcortyl in orabase', 'Allernaze', 'Aristocort', 'Aristocort aAristogel', 'Audicort', 'Aureocort', 'Azmacort', 'Flutex', 'Gppe ear dps capGppe ear oint', 'Kenacort', 'Kenalog', 'Kenalog in orabase', 'Kenalog-10Kenalog-40', 'Kenalog-80', 'Kenalog-h', 'NasacortNasacort allergy 24 hour', 'Nasacort aq', 'Nasacort hfa', 'NystadermalOracort', 'Oralone', 'Pevaryl t.c.', 'Remiderm', 'Remotic', 'SildermTri-Nasal', 'Tri-adcortyl', 'Triacet', 'Triacort', 'Triamcinolone acetonideTriamcinolone acetonide in absorbase', 'Triatex', 'Triderm', 'TriesenceTrivaris', 'Trymex', 'Vetalog', 'Xipere', 'Zilretta']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1960, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_226359', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_226644', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_226929', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_227214', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_227499', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_227784', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228069', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228354', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228639', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_228924', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_229209', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_229494', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_229779', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230064', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230349', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230634', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_230919', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_231204', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_231489', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_231774', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_232059', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}, {'UUID': 'DrugTargetsIndication121923_text_232344', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Tuberculosis, Pulmonary', 'efo_term': 'pulmonary tuberculosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.908 | Q16 | What Small molecule therapies have been approved by the FDA to treat choroiditis? | There are 2 Small molecule therapy drugs that are approved to treat choroiditis which are as follows: Prednisone and Dexamethasone. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "choroiditis" OR LOWER(mesh_heading) = "choroiditis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_217677', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_217885', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218093', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218301', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218509', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218717', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_218925', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219133', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219341', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219549', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219757', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_219965', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220173', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220381', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220589', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_220797', 'drugName': 'Prednisone', 'tradeNames_list': "['Cortan', 'Cortancyl', 'Decortisyl', 'Delta-dome', 'Deltasone', 'FernisoneLiquid pred', 'Lodotra', 'Meticorten', 'Orasone', 'Paracort', 'Prednicen-mPrednisone', 'Prednisone intensol', 'Rayos', 'Servisone', 'Sterapred']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1955, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_226375', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_226660', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_226945', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_227230', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_227515', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_227800', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228085', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228370', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228655', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_228940', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_229225', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_229510', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_229795', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230080', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230365', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230650', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_230935', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_231220', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_231505', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_231790', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_232075', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}, {'UUID': 'DrugTargetsIndication121923_text_232360', 'drugName': 'Dexamethasone', 'tradeNames_list': "['Aeroseb-dex', 'Dalalone', 'Decaderm', 'Decadron', 'Decadron-75', 'DecasprayDexacortisyl', 'Dexafree', 'Dexamethasone', 'Dexamethasone intensolDexone', 'Dexone 0.5', 'Dexone 0.75', 'Dexone 1.5', 'Dexone 4', 'DexsolDextenza', 'Dexycu kit', 'Dropodex', 'Gppe ear spy', 'Hemady', 'HexadrolKortico Injection', 'Martapan', 'Maxidex', 'Maxitrol', 'Oradexon', 'OtomizeOzurdex', 'Sofradex', 'Spersadex comp', 'Tobradex']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000113580', 'approvedSymbol': 'NR3C1', 'approvedName': 'nuclear receptor subfamily 3 group C member 1', 'yearOfFirstApproval': 1958, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Choroiditis', 'efo_term': 'choroiditis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1402 | Q16 | What Small molecule therapies have been approved by the FDA to treat opioid use disorder? | Buprenorphine is the only Small molecule therapy approved by the FDA to treat opioid use disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "opioid use disorder" OR LOWER(mesh_heading) = "opioid use disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_764058', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764086', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764114', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764142', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764170', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764198', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764226', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764254', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764282', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764310', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764338', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764366', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764394', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764422', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764450', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764478', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764506', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764534', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764562', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764590', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764618', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764646', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764674', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764702', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764730', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764758', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764786', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764814', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764842', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764870', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764898', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764926', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764954', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_764982', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765010', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765038', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765066', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765094', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765122', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765150', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765178', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765206', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765234', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765262', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765290', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000112038', 'approvedSymbol': 'OPRM1', 'approvedName': 'opioid receptor mu 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765318', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765346', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765374', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765402', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765430', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765458', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765486', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765514', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765542', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765570', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765598', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765626', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765654', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765682', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765710', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765738', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765766', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765794', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765822', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765850', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765878', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765906', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765934', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765962', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_765990', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766018', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766046', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766074', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766102', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766130', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766158', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766186', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766214', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766242', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766270', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766298', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766326', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766354', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766382', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766410', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766438', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766466', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766494', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766522', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}, {'UUID': 'DrugTargetsIndication121923_text_766550', 'drugName': 'Buprenorphine', 'tradeNames_list': "['Bupeaze', 'Buplast', 'Butec', 'Butrans', 'Hapoctasin', 'Panitaz', 'PrenotrixReletrans', 'Sevodyne', 'Sublocade', 'Temgesic', 'Tephine', 'Transtec']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000082556', 'approvedSymbol': 'OPRK1', 'approvedName': 'opioid receptor kappa 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Opioid-Related Disorders', 'efo_term': 'opioid use disorder'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1035 | Q16 | What Small molecule therapies have been approved by the FDA to treat epistaxis? | There are no drug Small molecule therapies approved to treat epistaxis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "epistaxis" OR LOWER(mesh_heading) = "epistaxis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.345 | Q16 | What Small molecule therapies have been approved by the FDA to treat Arrhythmogenic right ventricular dysplasia? | There are no drug Small molecule therapies approved to treat Arrhythmogenic right ventricular dysplasia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "arrhythmogenic right ventricular dysplasia" OR LOWER(mesh_heading) = "arrhythmogenic right ventricular dysplasia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.764 | Q16 | What Small molecule therapies have been approved by the FDA to treat angioedema? | There are 2 Small molecule therapy drugs that are approved to treat angioedema which are as follows: Epinephrine and Carbinoxamine Maleate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "angioedema" OR LOWER(mesh_heading) = "angioedema") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_360828', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_360881', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_360934', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_360987', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361040', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361093', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361146', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361199', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361252', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361305', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361358', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361411', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361464', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361517', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361570', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361623', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361676', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361729', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361782', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361835', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361888', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361941', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_361994', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362047', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362100', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362153', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362206', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362259', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362312', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362365', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362418', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362471', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362524', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362577', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362630', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362683', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362736', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362789', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362842', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362895', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_362948', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363001', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363054', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363107', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363160', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363213', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363266', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363319', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363372', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363425', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363478', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363531', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363584', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363637', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363690', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363743', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363796', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363849', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363902', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_363955', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364008', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364061', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364114', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364167', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364220', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364273', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364326', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364379', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364432', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364485', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364538', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364591', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364644', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364697', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364750', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364803', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364856', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364909', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_364962', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365015', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365068', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365121', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365174', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365227', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365280', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365333', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365386', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365439', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365492', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365545', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365598', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365651', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365704', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365757', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365810', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365863', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365916', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_365969', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_366022', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}, {'UUID': 'DrugTargetsIndication121923_text_366075', 'drugName': 'Epinephrine', 'tradeNames_list': "['Adren co', 'Adrenaclick', 'Adrenalin', 'Ana-Kit', 'Ana-guard', 'AnapenAnaphylactic shock drug kit', 'Asma-vydrin', 'Asthmahaler', 'Auvi-qBronkaid mist', 'Brovon', 'Emerade', 'Epi e z pen jr', 'EpinephrineEpinephrine (copackaged)', 'Epipen', 'Epipen e z pen', 'Epipen jrEpipen jr.', 'Eppy', 'Gppe inh soln', 'Jext', 'Medihaler-epi', 'PrimatenePrimatene mist', 'Riddobron', 'Riddofan', 'Rybarvin', 'SimpleneSoln made to rybarvin for', 'Sus-Phrine', 'Sus-Phrine Sulfite-FreeSus-phrine sulfite free', 'Symjepi', 'Twinject 0.15', 'Twinject 0.3']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000120907', 'approvedSymbol': 'ADRA1A', 'approvedName': 'adrenoceptor alpha 1A', 'yearOfFirstApproval': 1976, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angioedema', 'efo_term': 'angioedema'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1585 | Q16 | What Small molecule therapies have been approved by the FDA to treat retinopathy of prematurity? | There are no drug Small molecule therapies approved to treat retinopathy of prematurity. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "retinopathy of prematurity" OR LOWER(mesh_heading) = "retinopathy of prematurity") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.466 | Q16 | What Small molecule therapies have been approved by the FDA to treat HIV infection? | There are 2 Small molecule therapy drugs that are approved to treat HIV infection which are as follows: Maraviroc and Cobicistat. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hiv infection" OR LOWER(mesh_heading) = "hiv infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_938286', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938307', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938328', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938349', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938370', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938391', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938412', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938433', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938454', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938475', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938496', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938517', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938538', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938559', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_938580', 'drugName': 'Maraviroc', 'tradeNames_list': "['Celsentri', 'Selzentry']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000160791', 'approvedSymbol': 'CCR5', 'approvedName': 'C-C motif chemokine receptor 5', 'yearOfFirstApproval': 2007, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148778', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148789', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148800', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148811', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160868', 'approvedSymbol': 'CYP3A4', 'approvedName': 'cytochrome P450 family 3 subfamily A member 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148822', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148833', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148844', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148855', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106258', 'approvedSymbol': 'CYP3A5', 'approvedName': 'cytochrome P450 family 3 subfamily A member 5', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148866', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148877', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148888', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148899', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000021461', 'approvedSymbol': 'CYP3A43', 'approvedName': 'cytochrome P450 family 3 subfamily A member 43', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148910', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148921', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148932', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}, {'UUID': 'DrugTargetsIndication121923_text_1148943', 'drugName': 'Cobicistat', 'tradeNames_list': "['Tybost']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160870', 'approvedSymbol': 'CYP3A7', 'approvedName': 'cytochrome P450 family 3 subfamily A member 7', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'HIV Infections', 'efo_term': 'HIV infection'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.539 | Q16 | What Small molecule therapies have been approved by the FDA to treat Malignant Bone Neoplasm? | There are no drug Small molecule therapies approved to treat Malignant Bone Neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant bone neoplasm" OR LOWER(mesh_heading) = "malignant bone neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.574 | Q16 | What Small molecule therapies have been approved by the FDA to treat Oppositional defiant disorder? | There are no drug Small molecule therapies approved to treat Oppositional defiant disorder. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "oppositional defiant disorder" OR LOWER(mesh_heading) = "oppositional defiant disorder") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1625 | Q16 | What Small molecule therapies have been approved by the FDA to treat signet ring cell carcinoma? | There are no drug Small molecule therapies approved to treat signet ring cell carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "signet ring cell carcinoma" OR LOWER(mesh_heading) = "signet ring cell carcinoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.785 | Q16 | What Small molecule therapies have been approved by the FDA to treat appendix cancer? | There are no drug Small molecule therapies approved to treat appendix cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "appendix cancer" OR LOWER(mesh_heading) = "appendix cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.613 | Q16 | What Small molecule therapies have been approved by the FDA to treat Respiratory Syncytial Virus Infection? | There are no drug Small molecule therapies approved to treat Respiratory Syncytial Virus Infection. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "respiratory syncytial virus infection" OR LOWER(mesh_heading) = "respiratory syncytial virus infection") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1527 | Q16 | What Small molecule therapies have been approved by the FDA to treat primary myelofibrosis? | There are 3 Small molecule therapy drugs that are approved to treat primary myelofibrosis which are as follows: Ruxolitinib Phosphate, Fedratinib Hydrochloride, and Pacritinib Citrate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "primary myelofibrosis" OR LOWER(mesh_heading) = "primary myelofibrosis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_843626', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843628', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843639', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843641', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843652', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843654', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843665', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843667', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843678', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843680', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843691', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843693', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843704', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843706', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843717', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843719', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843730', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843732', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843743', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843745', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843756', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843758', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843769', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843771', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843782', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843784', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843795', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843797', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843808', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843810', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843821', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843823', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843834', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843836', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843847', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843849', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843860', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843862', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843873', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843875', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843886', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843888', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843899', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843901', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843912', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843914', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843925', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843927', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843938', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843940', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843951', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843953', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843964', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843966', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843977', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843979', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843990', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_843992', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844003', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844005', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844016', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844018', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844029', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844031', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844042', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844044', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844055', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844057', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844068', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844070', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844081', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844083', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844094', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844096', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844107', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844109', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844120', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844122', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844133', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844135', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844146', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844148', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844159', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844161', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844172', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844174', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844185', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844187', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844198', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844200', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844211', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844213', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844224', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844226', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844237', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844239', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844250', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844252', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844263', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'Myelofibrosis'}, {'UUID': 'DrugTargetsIndication121923_text_844265', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_list': "['Jakafi', 'Opzelura']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162434', 'approvedSymbol': 'JAK1', 'approvedName': 'Janus kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Primary Myelofibrosis', 'efo_term': 'primary myelofibrosis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.291 | Q16 | What Protein therapies have been approved by the FDA to treat severe aplastic anemia? | There are no drug Protein therapies approved to treat severe aplastic anemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "severe aplastic anemia" OR LOWER(mesh_heading) = "severe aplastic anemia") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1256 | Q16 | What Small molecule therapies have been approved by the FDA to treat liver cancer? | There are no drug Small molecule therapies approved to treat liver cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "liver cancer" OR LOWER(mesh_heading) = "liver cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.433 | Q16 | What Small molecule therapies have been approved by the FDA to treat Ewing sarcoma? | There are no drug Small molecule therapies approved to treat Ewing sarcoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ewing sarcoma" OR LOWER(mesh_heading) = "ewing sarcoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.418 | Q16 | What Small molecule therapies have been approved by the FDA to treat Dysmenorrhea? | There are 7 Small molecule therapy drugs that are approved to treat Dysmenorrhea which are as follows: Acetaminophen, Celecoxib, Aspirin, Diclofenac, Naproxen Sodium, Naproxen, and Ibuprofen. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "dysmenorrhea" OR LOWER(mesh_heading) = "dysmenorrhea") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_828734', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_828839', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_828944', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829049', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829154', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829259', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829364', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829469', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829574', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829679', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829784', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829889', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_829994', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830099', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830204', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830309', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830414', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830519', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830624', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830729', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830834', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_830939', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831044', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831149', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831254', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831359', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831464', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831569', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831674', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831779', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'opener', 'target': 'ENSG00000196689', 'approvedSymbol': 'TRPV1', 'approvedName': 'transient receptor potential cation channel subfamily V member 1', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831884', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_831989', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832094', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832199', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832304', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832409', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832514', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832619', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832724', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832829', 'drugName': 'Acetaminophen', 'tradeNames_list': '[\'Abdine\', \'Acephen\', \'Acetaminophen\', \'Alvedon\', \'Angiers\', \'CalpolCalpol six plus\', \'Calpol six plus fastmelts\', \'Child lemsip\', \'CupanolDafalgan\', \'Datril\', \'Disprol\', \'Disprol infant\', \'Disprol jnrDisprol paed\', \'Fennings\', \'Galpamol\', \'Hedex\', "InfadropsInfants\', feverallInjectapap", \'Junior parapaed\', \'Mandanol\', \'MedinolMedinol for children\', \'Medinol over 6\', \'Medinol under 6\', \'Medised plainMiradol\', \'Neopap\', \'Ofirmev\', \'Paldesic\', \'Panadol\', \'Panadol actifastPanadol actifast solb\', \'Panadol advan\', \'Panadol jnr\', \'Panadol oaPanaleve\', \'Panaleve 6 plus\', \'Paracetamol\', \'Paramin\', \'Parapaed jnrParapaed six plus\', \'Paravict\', \'Perfalgan\', \'Phenaphen\', \'PlacidexRimadol\', \'Salzone\', \'Tixymol\', \'Tramil 500\', \'Tylenol\']', 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000117480', 'approvedSymbol': 'FAAH', 'approvedName': 'fatty acid amide hydrolase', 'yearOfFirstApproval': 1968, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_832935', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833046', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833157', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833268', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833379', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833490', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833645', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833802', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_833959', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_834116', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_834273', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_834430', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_834587', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_834744', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_834901', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_835058', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_835215', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_835372', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_835529', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_835686', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_835843', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_836000', 'drugName': 'Aspirin', 'tradeNames_list': "['8-hour bayer', 'Acetosalic Acid', 'Acetylsalic acidAcetylsalicylic Acid', 'Alka rapid', 'Anadin all night', 'Angettes 75Aspirin', 'Aspro clr', 'Bayer extra strength aspirin for migraine painDanamep', 'Disprin cv', 'Disprin direct', 'Durlaza', 'Ecotrin', 'EnprinEqui-Prin', 'Gencardia', 'Levius', 'Max strgh aspro clr', 'MeasurinMicropirin ec', 'Nu-seals 300', 'Nu-seals 600', 'Nu-seals 75Nu-seals cardio 75', 'Paynocil', 'Platet', 'Platet 300', 'Postmi 300Postmi 75', 'Salicylic Acid Acetate', 'Vazalore']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1950, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_836975', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837005', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837035', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837065', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837095', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837125', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837155', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837185', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837215', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837245', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837275', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837305', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837335', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837365', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837395', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837425', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837455', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837485', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837515', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837545', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837575', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837605', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837635', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837665', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837695', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837725', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837755', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837785', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837815', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837845', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837875', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837905', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837935', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837965', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_837995', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_838025', 'drugName': 'Diclofenac', 'tradeNames_list': "['Cambia', 'Voltaren', 'Voltaren Ophthalmic', 'Voltaren Xr', 'ZorvolexZorvolex capsules']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000095303', 'approvedSymbol': 'PTGS1', 'approvedName': 'prostaglandin-endoperoxide synthase 1', 'yearOfFirstApproval': 1988, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_838043', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}, {'UUID': 'DrugTargetsIndication121923_text_838060', 'drugName': 'Naproxen Sodium', 'tradeNames_list': "['Aleve', 'Anaprox', 'Anaprox ds', 'Naprelan', 'Naproxen sodium', 'Synflex']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1980, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Dysmenorrhea', 'efo_term': 'Dysmenorrhea'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.622 | Q16 | What Small molecule therapies have been approved by the FDA to treat Shock? | There are no drug Small molecule therapies approved to treat Shock. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "shock" OR LOWER(mesh_heading) = "shock") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1686 | Q16 | What Small molecule therapies have been approved by the FDA to treat teratoma? | There are no drug Small molecule therapies approved to treat teratoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "teratoma" OR LOWER(mesh_heading) = "teratoma") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.211 | Q16 | What Protein therapies have been approved by the FDA to treat male infertility? | There are no drug Protein therapies approved to treat male infertility. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "male infertility" OR LOWER(mesh_heading) = "male infertility") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.249 | Q16 | What Protein therapies have been approved by the FDA to treat ovarian cancer? | There are no drug Protein therapies approved to treat ovarian cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "ovarian cancer" OR LOWER(mesh_heading) = "ovarian cancer") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.918 | Q16 | What Small molecule therapies have been approved by the FDA to treat chronic lymphocytic leukemia? | There are 7 Small molecule therapy drugs that are approved to treat chronic lymphocytic leukemia which are as follows: Fludarabine Phosphate, Idelalisib, Duvelisib, Venetoclax, Acalabrutinib, Ibrutinib, and Acalabrutinib Maleate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "chronic lymphocytic leukemia" OR LOWER(mesh_heading) = "chronic lymphocytic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_753951', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101868', 'approvedSymbol': 'POLA1', 'approvedName': 'DNA polymerase alpha 1, catalytic subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_754089', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000175482', 'approvedSymbol': 'POLD4', 'approvedName': 'DNA polymerase delta 4, accessory subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_754227', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077514', 'approvedSymbol': 'POLD3', 'approvedName': 'DNA polymerase delta 3, accessory subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_754365', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000062822', 'approvedSymbol': 'POLD1', 'approvedName': 'DNA polymerase delta 1, catalytic subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_754503', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000106628', 'approvedSymbol': 'POLD2', 'approvedName': 'DNA polymerase delta 2, accessory subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_754641', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000177084', 'approvedSymbol': 'POLE', 'approvedName': 'DNA polymerase epsilon, catalytic subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_754779', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000014138', 'approvedSymbol': 'POLA2', 'approvedName': 'DNA polymerase alpha 2, accessory subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_754917', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198056', 'approvedSymbol': 'PRIM1', 'approvedName': 'DNA primase subunit 1', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_755055', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146143', 'approvedSymbol': 'PRIM2', 'approvedName': 'DNA primase subunit 2', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_755193', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000100479', 'approvedSymbol': 'POLE2', 'approvedName': 'DNA polymerase epsilon 2, accessory subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_755331', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000148229', 'approvedSymbol': 'POLE3', 'approvedName': 'DNA polymerase epsilon 3, accessory subunit', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_755469', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000167325', 'approvedSymbol': 'RRM1', 'approvedName': 'ribonucleotide reductase catalytic subunit M1', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_755607', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000048392', 'approvedSymbol': 'RRM2B', 'approvedName': 'ribonucleotide reductase regulatory TP53 inducible subunit M2B', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_755745', 'drugName': 'Fludarabine Phosphate', 'tradeNames_list': "['Fludara', 'Fludarabine phosphate', 'Oforta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171848', 'approvedSymbol': 'RRM2', 'approvedName': 'ribonucleotide reductase regulatory subunit M2', 'yearOfFirstApproval': 1991, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858394', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858413', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858432', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858451', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858470', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858489', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858508', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858527', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858546', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858565', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858584', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858603', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858622', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858641', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858660', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858679', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858698', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858717', 'drugName': 'Idelalisib', 'tradeNames_list': "['Zydelig']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2014, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858735', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858755', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858775', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858795', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858815', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858835', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858855', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858875', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858895', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858915', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858935', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858955', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858975', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_858995', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171608', 'approvedSymbol': 'PIK3CD', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859015', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859035', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859055', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859075', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859095', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859115', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859135', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859155', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859175', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859195', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859215', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859235', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859255', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_859275', 'drugName': 'Duvelisib', 'tradeNames_list': "['Copiktra']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000105851', 'approvedSymbol': 'PIK3CG', 'approvedName': 'phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma', 'yearOfFirstApproval': 2018, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989691', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989729', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989767', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989805', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989843', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989881', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989919', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989957', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_989995', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990033', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990071', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990109', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990147', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990185', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990223', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990261', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990299', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990337', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990375', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990413', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990451', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990489', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990527', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990565', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990603', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990641', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990679', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990717', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990755', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990793', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990831', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990869', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990907', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990945', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_990983', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_991021', 'drugName': 'Venetoclax', 'tradeNames_list': "['Venclexta']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000171791', 'approvedSymbol': 'BCL2', 'approvedName': 'BCL2 apoptosis regulator', 'yearOfFirstApproval': 2016, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_993976', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_993999', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_994022', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}, {'UUID': 'DrugTargetsIndication121923_text_994045', 'drugName': 'Acalabrutinib', 'tradeNames_list': "['Calquence']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000010671', 'approvedSymbol': 'BTK', 'approvedName': 'Bruton tyrosine kinase', 'yearOfFirstApproval': 2017, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Leukemia, Lymphocytic, Chronic, B-Cell', 'efo_term': 'chronic lymphocytic leukemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.430 | Q16 | What Small molecule therapies have been approved by the FDA to treat Erythema? | Brimonidine Tartrate is the only Small molecule therapy approved by the FDA to treat Erythema. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "erythema" OR LOWER(mesh_heading) = "erythema") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1034050', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034065', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034080', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034095', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034110', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034125', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034140', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034155', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034170', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034185', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034200', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034215', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034230', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034245', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034260', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034275', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034290', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034305', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034320', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034335', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034350', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034365', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034380', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034395', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034410', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034425', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034440', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034455', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000150594', 'approvedSymbol': 'ADRA2A', 'approvedName': 'adrenoceptor alpha 2A', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034470', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034485', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034500', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034515', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034530', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034545', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034560', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034575', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034590', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034605', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034620', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034635', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034650', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034665', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034680', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034695', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034710', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034725', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034740', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034755', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034770', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034785', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034800', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034815', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034830', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034845', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034860', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034875', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000184160', 'approvedSymbol': 'ADRA2C', 'approvedName': 'adrenoceptor alpha 2C', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034890', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034905', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034920', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034935', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034950', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034965', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034980', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1034995', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035010', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035025', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035040', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035055', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035070', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035085', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035100', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035115', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035130', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035145', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035160', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035175', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035190', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035205', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035220', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035235', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035250', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035265', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035280', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}, {'UUID': 'DrugTargetsIndication121923_text_1035295', 'drugName': 'Brimonidine Tartrate', 'tradeNames_list': "['Alphagan', 'Alphagan p', 'Brimonidine tartrate', 'Brymont', 'LumifyMirvaso', 'Qoliana']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000274286', 'approvedSymbol': 'ADRA2B', 'approvedName': 'adrenoceptor alpha 2B', 'yearOfFirstApproval': 1996, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Erythema', 'efo_term': 'Erythema'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1063 | Q16 | What Small molecule therapies have been approved by the FDA to treat familial partial lipodystrophy? | There are no drug Small molecule therapies approved to treat familial partial lipodystrophy. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial partial lipodystrophy" OR LOWER(mesh_heading) = "familial partial lipodystrophy") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.50 | Q16 | What Protein therapies have been approved by the FDA to treat Lymphoma, AIDS-Related? | There are no drug Protein therapies approved to treat Lymphoma, AIDS-Related. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "lymphoma, aids-related" OR LOWER(mesh_heading) = "lymphoma, aids-related") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1540 | Q16 | What Small molecule therapies have been approved by the FDA to treat prostatitis? | There are no drug Small molecule therapies approved to treat prostatitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "prostatitis" OR LOWER(mesh_heading) = "prostatitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.946 | Q16 | What Small molecule therapies have been approved by the FDA to treat colorectal neoplasm? | Regorafenib is the only Small molecule therapy approved by the FDA to treat colorectal neoplasm. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "colorectal neoplasm" OR LOWER(mesh_heading) = "colorectal neoplasm") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_664066', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664102', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664138', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664174', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664210', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664246', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664282', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664318', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664354', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664390', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664426', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664462', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664498', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664534', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664570', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664606', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664642', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664678', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664714', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664750', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000097007', 'approvedSymbol': 'ABL1', 'approvedName': 'ABL proto-oncogene 1, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664786', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664822', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664858', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664894', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664930', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157764', 'approvedSymbol': 'BRAF', 'approvedName': 'B-Raf proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_664966', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665002', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665038', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665074', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665110', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665146', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665182', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665218', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665254', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665290', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665326', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665362', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665398', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665434', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665470', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000157404', 'approvedSymbol': 'KIT', 'approvedName': 'KIT proto-oncogene, receptor tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665506', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665542', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665578', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665614', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665650', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665686', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665722', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665758', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665794', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665830', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000113721', 'approvedSymbol': 'PDGFRB', 'approvedName': 'platelet derived growth factor receptor beta', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665866', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665902', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665938', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_665974', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666010', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000134853', 'approvedSymbol': 'PDGFRA', 'approvedName': 'platelet derived growth factor receptor alpha', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666046', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666082', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666118', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666154', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666190', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000132155', 'approvedSymbol': 'RAF1', 'approvedName': 'Raf-1 proto-oncogene, serine/threonine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666226', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666262', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666298', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666334', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666370', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666406', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666442', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666478', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666514', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666550', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000111816', 'approvedSymbol': 'FRK', 'approvedName': 'fyn related Src family tyrosine kinase', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666586', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666622', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666658', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666694', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666730', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000198400', 'approvedSymbol': 'NTRK1', 'approvedName': 'neurotrophic receptor tyrosine kinase 1', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666766', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666802', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666838', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666874', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666910', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666946', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_666982', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667018', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667054', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667090', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000162733', 'approvedSymbol': 'DDR2', 'approvedName': 'discoidin domain receptor tyrosine kinase 2', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667126', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667162', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667198', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667234', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_667270', 'drugName': 'Regorafenib', 'tradeNames_list': "['Stivarga']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000185386', 'approvedSymbol': 'MAPK11', 'approvedName': 'mitogen-activated protein kinase 11', 'yearOfFirstApproval': 2012, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Colorectal Neoplasms', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_832945', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_833056', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_833167', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_833278', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_833389', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm'}, {'UUID': 'DrugTargetsIndication121923_text_833500', 'drugName': 'Celecoxib', 'tradeNames_list': "['Celebra', 'Celebrex', 'Celecoxib', 'Elyxyb', 'Onsenal']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000073756', 'approvedSymbol': 'PTGS2', 'approvedName': 'prostaglandin-endoperoxide synthase 2', 'yearOfFirstApproval': 1998, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Adenomatous Polyposis Coli', 'efo_term': 'colorectal neoplasm'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.197 | Q16 | What Protein therapies have been approved by the FDA to treat kidney failure? | There are no drug Protein therapies approved to treat kidney failure. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "kidney failure" OR LOWER(mesh_heading) = "kidney failure") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1302 | Q16 | What Small molecule therapies have been approved by the FDA to treat membranous glomerulonephritis? | There are no drug Small molecule therapies approved to treat membranous glomerulonephritis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "membranous glomerulonephritis" OR LOWER(mesh_heading) = "membranous glomerulonephritis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.817 | Q16 | What Small molecule therapies have been approved by the FDA to treat bile duct cancer? | There are no drug Small molecule therapies approved to treat bile duct cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "bile duct cancer" OR LOWER(mesh_heading) = "bile duct cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1370 | Q16 | What Small molecule therapies have been approved by the FDA to treat neuralgia? | There are 5 Small molecule therapy drugs that are approved to treat neuralgia which are as follows: Lidocaine, Pregabalin, Gabapentin Enacarbil, Gabapentin, and Capsaicin. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "neuralgia" OR LOWER(mesh_heading) = "neuralgia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_205998', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206014', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206030', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206046', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206062', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206078', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206094', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206110', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206126', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206142', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206158', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206174', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206190', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206206', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206222', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206238', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000108576', 'approvedSymbol': 'SLC6A4', 'approvedName': 'solute carrier family 6 member 4', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206254', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206270', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206286', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206302', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206318', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206334', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206350', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206366', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206382', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206398', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206414', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206430', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206446', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206462', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206478', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_206494', 'drugName': 'Duloxetine Hydrochloride', 'tradeNames_list': "['Ariclaim', 'Cymbalta', 'Drizalma sprinkle', 'DuciltiaDuloxetine hydrochloride', 'Yentreve']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2004, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434247', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434252', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434257', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434262', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434267', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434272', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434277', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434282', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434287', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434292', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434297', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434302', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434307', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434312', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434317', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434322', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434327', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434332', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434337', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434342', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434347', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434352', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434357', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434362', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434367', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434372', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434377', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434382', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434387', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434392', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434397', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434402', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434407', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434412', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434417', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434422', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434427', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434432', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434437', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434442', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434447', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434452', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434457', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434462', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434467', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434472', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434477', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434482', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434487', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434492', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434497', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434502', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434507', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434512', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434517', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434522', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434527', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434532', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434537', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434542', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434547', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434552', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434557', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434562', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434567', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434572', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434577', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}, {'UUID': 'DrugTargetsIndication121923_text_434582', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_list': "['Nucynta', 'Nucynta er', 'Palexia']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000103546', 'approvedSymbol': 'SLC6A2', 'approvedName': 'solute carrier family 6 member 2', 'yearOfFirstApproval': 2008, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuralgia', 'efo_term': 'neuropathic pain'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.763 | Q16 | What Small molecule therapies have been approved by the FDA to treat angina pectoris? | There are 5 Small molecule therapy drugs that are approved to treat angina pectoris which are as follows: Ranolazine, Propranolol Hydrochloride, Metoprolol Succinate, Nitroglycerin, and Amlodipine Besylate. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "angina pectoris" OR LOWER(mesh_heading) = "angina pectoris") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_662708', 'drugName': 'Ranolazine', 'tradeNames_list': "['Aspruzyo sprinkle', 'Ranexa', 'Ranolazine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000183873', 'approvedSymbol': 'SCN5A', 'approvedName': 'sodium voltage-gated channel alpha subunit 5', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_662725', 'drugName': 'Ranolazine', 'tradeNames_list': "['Aspruzyo sprinkle', 'Ranexa', 'Ranolazine']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000007314', 'approvedSymbol': 'SCN4A', 'approvedName': 'sodium voltage-gated channel alpha subunit 4', 'yearOfFirstApproval': 2006, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937019', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937042', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000169252', 'approvedSymbol': 'ADRB2', 'approvedName': 'adrenoceptor beta 2', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937065', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937088', 'drugName': 'Propranolol Hydrochloride', 'tradeNames_list': "['Angilol', 'Apsolol', 'Avlocardyl', 'Bedranol', 'Bedranol s.r.', 'BerkololBeta-prograne mr', 'Betadur cr', 'Cardinol', 'DupromexHalf beta-prograne mr', 'Half propanix la', 'Half propatard laHalf-beprane cr', 'Half-betadur cr', 'Half-inderal la', 'HemangeolInderal', 'Inderal la', 'Innopran', 'Innopran xl', 'LederpronolLopranol la', 'Probeta la', 'Propanix la', 'Propanix-10', 'Propanix-160Propanix-160 sr', 'Propanix-40', 'Propanix-80', 'Propatard laPropranolol hydrochloride', 'Propranolol hydrochloride intensolRapranol sr', 'Sagittol', 'Slo-blok', 'Slo-pro', 'Sloprolol', 'SyprolTesnol']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1967, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937603', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937614', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937625', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937636', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937647', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937658', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937669', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_937680', 'drugName': 'Metoprolol Succinate', 'tradeNames_list': "['Kapspargo sprinkle', 'Metoprolol succinate', 'Toprol', 'Toprol XlToprol-xl']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000043591', 'approvedSymbol': 'ADRB1', 'approvedName': 'adrenoceptor beta 1', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972481', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972515', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972549', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972583', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972617', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000152402', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972651', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000152402', 'approvedSymbol': 'GUCY1A2', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 2', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972685', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000164116', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_972719', 'drugName': 'Nitroglycerin', 'tradeNames_list': "['Coro-nitro', 'Deponit 10', 'Deponit 5', 'Glytrin', 'Gonitro', 'Lenitral 7.5Minitran', 'Minitran 10', 'Minitran 15', 'Minitran 5', 'NatiroseNitriderm tts', 'Nitro iv', 'Nitro-bid', 'Nitro-dur', 'Nitro-mack retNitrocine', 'Nitrocontin continus', 'Nitroglycerin', 'NitrolNitrolingual', 'Nitrolingual pumpspray', 'Nitromin', 'Nitromist', 'NitronalNitrostat', 'Percutol', 'Rectiv', 'Rectogesic', 'Suscard buccal', 'SustacTransderm-nitro', 'Transiderm-nitro 10', 'Transiderm-nitro 5', 'TridilTrintek 10', 'Trintek 15', 'Trintek 5']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000164116', 'approvedSymbol': 'GUCY1A1', 'approvedName': 'guanylate cyclase 1 soluble subunit alpha 1', 'yearOfFirstApproval': 1981, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043668', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043669', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043682', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043683', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043696', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043697', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043710', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043711', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043724', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043725', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043738', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043739', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000151067', 'approvedSymbol': 'CACNA1C', 'approvedName': 'calcium voltage-gated channel subunit alpha1 C', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043752', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043753', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043766', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043767', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043780', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043781', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043794', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043795', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043808', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043809', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043822', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043823', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000081248', 'approvedSymbol': 'CACNA1S', 'approvedName': 'calcium voltage-gated channel subunit alpha1 S', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043836', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043837', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043850', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043851', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043864', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043865', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043878', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043879', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043892', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043893', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043906', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043907', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000157388', 'approvedSymbol': 'CACNA1D', 'approvedName': 'calcium voltage-gated channel subunit alpha1 D', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043920', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043921', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043934', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043935', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043948', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043949', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043962', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043963', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043976', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043977', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043990', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina Pectoris', 'efo_term': 'angina pectoris'}, {'UUID': 'DrugTargetsIndication121923_text_1043991', 'drugName': 'Amlodipine Besylate', 'tradeNames_list': "['Amlodipine besylate', 'Norliqva', 'Norvasc']", 'drugType': 'Small molecule', 'actionType': 'blocker', 'target': 'ENSG00000102001', 'approvedSymbol': 'CACNA1F', 'approvedName': 'calcium voltage-gated channel subunit alpha1 F', 'yearOfFirstApproval': 1992, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Angina, Stable', 'efo_term': 'angina pectoris'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.429 | Q16 | What Small molecule therapies have been approved by the FDA to treat Erdheim-Chester disease? | There are no drug Small molecule therapies approved to treat Erdheim-Chester disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "erdheim-chester disease" OR LOWER(mesh_heading) = "erdheim-chester disease") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1181 | Q16 | What Small molecule therapies have been approved by the FDA to treat idiopathic and/or familial pulmonary arterial hypertension? | There are 5 Small molecule therapy drugs that are approved to treat idiopathic and/or familial pulmonary arterial hypertension which are as follows: Selexipag, Riociguat, Macitentan, Ambrisentan, and Bosentan. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "idiopathic and/or familial pulmonary arterial hypertension" OR LOWER(mesh_heading) = "idiopathic and/or familial pulmonary arterial hypertension") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_246125', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246129', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246133', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246137', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246141', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246145', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246149', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246153', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246157', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246161', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246165', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246169', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246173', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246177', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246181', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246185', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246189', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246193', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246197', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246201', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246205', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246209', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246213', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246217', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246221', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246225', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246229', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246233', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246237', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246241', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246245', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246249', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246253', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246257', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246261', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246265', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246269', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246273', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246277', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246281', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246285', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246289', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246293', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246297', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246301', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246305', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246309', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246313', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246317', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246321', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246325', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_246329', 'drugName': 'Selexipag', 'tradeNames_list': "['Uptravi']", 'drugType': 'Small molecule', 'actionType': 'agonist', 'target': 'ENSG00000160013', 'approvedSymbol': 'PTGIR', 'approvedName': 'prostaglandin I2 receptor', 'yearOfFirstApproval': 2015, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972915', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972927', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972939', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972951', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972963', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972975', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972987', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_972999', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973011', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973023', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973035', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973047', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973059', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973071', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973083', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973095', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973107', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973119', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973131', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973143', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973155', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973167', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973179', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973191', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973203', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000061918', 'approvedSymbol': 'GUCY1B1', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 1', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973215', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973227', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973239', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973251', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973263', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973275', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973287', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973299', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973311', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973323', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973335', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973347', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973359', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973371', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973383', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973395', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973407', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973419', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973431', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973443', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973455', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973467', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}, {'UUID': 'DrugTargetsIndication121923_text_973479', 'drugName': 'Riociguat', 'tradeNames_list': "['Adempas', 'Bay 63-2521']", 'drugType': 'Small molecule', 'actionType': 'positive allosteric modulator', 'target': 'ENSG00000123201', 'approvedSymbol': 'GUCY1B2', 'approvedName': 'guanylate cyclase 1 soluble subunit beta 2 (pseudogene)', 'yearOfFirstApproval': 2013, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Familial Primary Pulmonary Hypertension', 'efo_term': 'idiopathic and/or familial pulmonary arterial hypertension'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.355 | Q16 | What Small molecule therapies have been approved by the FDA to treat B-cell acute lymphoblastic leukemia? | There are no drug Small molecule therapies approved to treat B-cell acute lymphoblastic leukemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "b-cell acute lymphoblastic leukemia" OR LOWER(mesh_heading) = "b-cell acute lymphoblastic leukemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1694 | Q16 | What Small molecule therapies have been approved by the FDA to treat thyroid cancer? | There are 9 Small molecule therapy drugs that are approved to treat thyroid cancer which are as follows: Vandetanib, Cabozantinib S-Malate, Sorafenib Tosylate, Lenvatinib Mesylate, Lenvatinib, Dabrafenib Mesylate, Levothyroxine Sodium, Trametinib Dimethyl Sulfoxide, and Selpercatinib. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thyroid cancer" OR LOWER(mesh_heading) = "thyroid cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_209948', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_209996', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210044', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210092', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210140', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210188', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000146648', 'approvedSymbol': 'EGFR', 'approvedName': 'epidermal growth factor receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210236', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210284', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210332', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210380', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210428', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210476', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000065361', 'approvedSymbol': 'ERBB3', 'approvedName': 'erb-b2 receptor tyrosine kinase 3', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210524', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210572', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210620', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210668', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210716', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210764', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000128052', 'approvedSymbol': 'KDR', 'approvedName': 'kinase insert domain receptor', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210812', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210860', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210908', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_210956', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211004', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211052', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000197122', 'approvedSymbol': 'SRC', 'approvedName': 'SRC proto-oncogene, non-receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211100', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211148', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211196', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211244', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211292', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211340', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000120156', 'approvedSymbol': 'TEK', 'approvedName': 'TEK receptor tyrosine kinase', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211388', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211436', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211484', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211532', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211580', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211628', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000141736', 'approvedSymbol': 'ERBB2', 'approvedName': 'erb-b2 receptor tyrosine kinase 2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211676', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211724', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211772', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211820', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211868', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211916', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000102755', 'approvedSymbol': 'FLT1', 'approvedName': 'fms related receptor tyrosine kinase 1', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_211964', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212012', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212060', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212108', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212156', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212204', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000037280', 'approvedSymbol': 'FLT4', 'approvedName': 'fms related receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212252', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212300', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212348', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212396', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212444', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212492', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000142627', 'approvedSymbol': 'EPHA2', 'approvedName': 'EPH receptor A2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212540', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212588', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212636', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212684', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212732', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212780', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000165731', 'approvedSymbol': 'RET', 'approvedName': 'ret proto-oncogene', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212828', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212876', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212924', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_212972', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213020', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213068', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000178568', 'approvedSymbol': 'ERBB4', 'approvedName': 'erb-b2 receptor tyrosine kinase 4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213116', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213164', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213212', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213260', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213308', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213356', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000196411', 'approvedSymbol': 'EPHB4', 'approvedName': 'EPH receptor B4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213404', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213452', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213500', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213548', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213596', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213644', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000101213', 'approvedSymbol': 'PTK6', 'approvedName': 'protein tyrosine kinase 6', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213692', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213740', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213788', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213836', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213884', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213932', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000133216', 'approvedSymbol': 'EPHB2', 'approvedName': 'EPH receptor B2', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_213980', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214028', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214076', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214124', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214172', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214220', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000145242', 'approvedSymbol': 'EPHA5', 'approvedName': 'EPH receptor A5', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214268', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214316', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214364', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214412', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214460', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214508', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000116106', 'approvedSymbol': 'EPHA4', 'approvedName': 'EPH receptor A4', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214556', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214604', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214652', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}, {'UUID': 'DrugTargetsIndication121923_text_214700', 'drugName': 'Vandetanib', 'tradeNames_list': "['Caprelsa', 'Zactima']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000070886', 'approvedSymbol': 'EPHA8', 'approvedName': 'EPH receptor A8', 'yearOfFirstApproval': 2011, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Thyroid Neoplasms', 'efo_term': 'thyroid cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.490 | Q16 | What Small molecule therapies have been approved by the FDA to treat Herpetic encephalitis? | There are no drug Small molecule therapies approved to treat Herpetic encephalitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "herpetic encephalitis" OR LOWER(mesh_heading) = "herpetic encephalitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1059 | Q16 | What Small molecule therapies have been approved by the FDA to treat familial hemolytic anemia? | Mitapivat Sulfate is the only Small molecule therapy approved by the FDA to treat familial hemolytic anemia. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "familial hemolytic anemia" OR LOWER(mesh_heading) = "familial hemolytic anemia") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1193473', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193474', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193475', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193476', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193477', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193478', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193479', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193480', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193481', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193482', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193483', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193484', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193485', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193486', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193487', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193488', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193489', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193490', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193491', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193492', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}, {'UUID': 'DrugTargetsIndication121923_text_1193493', 'drugName': 'Mitapivat Sulfate', 'tradeNames_list': "['Pyrukynd']", 'drugType': 'Small molecule', 'actionType': 'activator', 'target': 'ENSG00000143627', 'approvedSymbol': 'PKLR', 'approvedName': 'pyruvate kinase L/R', 'yearOfFirstApproval': 2022, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anemia, Hemolytic, Congenital', 'efo_term': 'familial hemolytic anemia'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1729 | Q16 | What Small molecule therapies have been approved by the FDA to treat urinary bladder cancer? | Erdafitinib is the only Small molecule therapy approved by the FDA to treat urinary bladder cancer. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "urinary bladder cancer" OR LOWER(mesh_heading) = "urinary bladder cancer") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_707097', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707113', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707129', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707145', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707161', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707177', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707193', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707209', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707225', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707241', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707257', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707273', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707289', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707305', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707321', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707337', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707353', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707369', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707385', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707401', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707417', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707433', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707449', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707465', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000077782', 'approvedSymbol': 'FGFR1', 'approvedName': 'fibroblast growth factor receptor 1', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707481', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707497', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707513', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707529', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707545', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707561', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707577', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707593', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707609', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707625', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707641', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707657', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707673', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707689', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707705', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707721', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707737', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707753', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707769', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707785', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707801', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707817', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707833', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707849', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000068078', 'approvedSymbol': 'FGFR3', 'approvedName': 'fibroblast growth factor receptor 3', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707865', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707881', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707897', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707913', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707929', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707945', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707961', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707977', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_707993', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708009', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708025', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708041', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708057', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708073', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708089', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708105', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708121', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708137', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708153', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708169', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708185', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708201', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708217', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708233', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000066468', 'approvedSymbol': 'FGFR2', 'approvedName': 'fibroblast growth factor receptor 2', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708249', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708265', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708281', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708297', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708313', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708329', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708345', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708361', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708377', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708393', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708409', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708425', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708441', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708457', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708473', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708489', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708505', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708521', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708537', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708553', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708569', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708585', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708601', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}, {'UUID': 'DrugTargetsIndication121923_text_708617', 'drugName': 'Erdafitinib', 'tradeNames_list': "['Balversa']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000160867', 'approvedSymbol': 'FGFR4', 'approvedName': 'fibroblast growth factor receptor 4', 'yearOfFirstApproval': 2019, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Urinary Bladder Neoplasms', 'efo_term': 'urinary bladder cancer'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.214 | Q16 | What Protein therapies have been approved by the FDA to treat medullary thyroid gland carcinoma? | There are no drug Protein therapies approved to treat medullary thyroid gland carcinoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "medullary thyroid gland carcinoma" OR LOWER(mesh_heading) = "medullary thyroid gland carcinoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.79 | Q16 | What Protein therapies have been approved by the FDA to treat acute disease? | There are no drug Protein therapies approved to treat acute disease. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "acute disease" OR LOWER(mesh_heading) = "acute disease") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.775 | Q16 | What Small molecule therapies have been approved by the FDA to treat anti-neutrophil antibody associated vasculitis? | Avacopan is the only Small molecule therapy approved by the FDA to treat anti-neutrophil antibody associated vasculitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "anti-neutrophil antibody associated vasculitis" OR LOWER(mesh_heading) = "anti-neutrophil antibody associated vasculitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1191848', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis'}, {'UUID': 'DrugTargetsIndication121923_text_1191856', 'drugName': 'Avacopan', 'tradeNames_list': "['Tavneos']", 'drugType': 'Small molecule', 'actionType': 'antagonist', 'target': 'ENSG00000197405', 'approvedSymbol': 'C5AR1', 'approvedName': 'complement C5a receptor 1', 'yearOfFirstApproval': 2021, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis', 'efo_term': 'anti-neutrophil antibody associated vasculitis'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.263 | Q16 | What Protein therapies have been approved by the FDA to treat posterior uveitis? | There are no drug Protein therapies approved to treat posterior uveitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "posterior uveitis" OR LOWER(mesh_heading) = "posterior uveitis") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.74 | Q16 | What Protein therapies have been approved by the FDA to treat abnormal glucose tolerance? | There are no drug Protein therapies approved to treat abnormal glucose tolerance. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "abnormal glucose tolerance" OR LOWER(mesh_heading) = "abnormal glucose tolerance") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.70 | Q16 | What Protein therapies have been approved by the FDA to treat Thymoma? | There are no drug Protein therapies approved to treat Thymoma. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "thymoma" OR LOWER(mesh_heading) = "thymoma") AND LOWER(drugType) = "protein" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1753 | Q16 | What Small molecule therapies have been approved by the FDA to treat viral conjunctivitis? | There are no drug Small molecule therapies approved to treat viral conjunctivitis. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "viral conjunctivitis" OR LOWER(mesh_heading) = "viral conjunctivitis") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1287 | Q16 | What Small molecule therapies have been approved by the FDA to treat malignant peripheral nerve sheath tumor? | There are no drug Small molecule therapies approved to treat malignant peripheral nerve sheath tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "malignant peripheral nerve sheath tumor" OR LOWER(mesh_heading) = "malignant peripheral nerve sheath tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.424 | Q16 | What Small molecule therapies have been approved by the FDA to treat Eisenmenger syndrome? | There are no drug Small molecule therapies approved to treat Eisenmenger syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "eisenmenger syndrome" OR LOWER(mesh_heading) = "eisenmenger syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.1551 | Q16 | What Small molecule therapies have been approved by the FDA to treat pulmonary neuroendocrine tumor? | Everolimus is the only Small molecule therapy approved by the FDA to treat pulmonary neuroendocrine tumor. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "pulmonary neuroendocrine tumor" OR LOWER(mesh_heading) = "pulmonary neuroendocrine tumor") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [{'UUID': 'DrugTargetsIndication121923_text_1084962', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085097', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085232', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085367', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085502', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085637', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085772', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1085907', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086042', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086177', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086312', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086447', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086582', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086717', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086852', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1086987', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087122', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087257', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087392', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087527', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087662', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087797', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1087932', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088067', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088202', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088337', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088472', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088607', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088742', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1088877', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089012', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089147', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089282', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089417', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089552', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089687', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089822', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1089957', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090092', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090227', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090362', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090497', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}, {'UUID': 'DrugTargetsIndication121923_text_1090632', 'drugName': 'Everolimus', 'tradeNames_list': "['Afinitor', 'Afinitor disperz', 'Certican', 'Votubia', 'Zortress']", 'drugType': 'Small molecule', 'actionType': 'inhibitor', 'target': 'ENSG00000088832', 'approvedSymbol': 'FKBP1A', 'approvedName': 'FKBP prolyl isomerase 1A', 'yearOfFirstApproval': 2009, 'max_phase_for_ind': 4.0, 'mesh_heading': 'Neuroendocrine Tumors', 'efo_term': 'pulmonary neuroendocrine tumor'}] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Q16.499 | Q16 | What Small molecule therapies have been approved by the FDA to treat Hypereosinophilic syndrome? | There are no drug Small molecule therapies approved to treat Hypereosinophilic syndrome. | SELECT DISTINCT UUID, drugName, tradeNames_list, drugType, actionType, target, approvedSymbol, approvedName, yearOfFirstApproval, max_phase_for_ind, mesh_heading, efo_term
FROM `{project_id}.{dataset_name}.DrugTargets_IndicationsAndTherapeuticUses`
WHERE (LOWER(efo_term) = "hypereosinophilic syndrome" OR LOWER(mesh_heading) = "hypereosinophilic syndrome") AND LOWER(drugType) = "small molecule" AND yearOfFirstApproval > 0 AND max_phase_for_ind = 4.0
LIMIT 100 | [] | refined | Distinct, Multi-Filter, Similarity Search | Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.